Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06561646

To Evaluate the Effectiveness and Safety of the Single-port Robotic-assisted Breast Surgery in Breast Cancer

The new technology of robotic surgery system, as an emerging technology, has shown certain application prospects in breast surgery. However, the new technology of robotic surgery system in China in the treatment of breast cancer is still in the exploratory stage and needs to be further improved. This prospective, single-center, single-arm clinical study was conducted to use the abdominal endoscopic surgery system and evaluate the effectiveness and safety of the single-port robotic-assisted breast surgery in breast cancer.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–75 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

The First Affiliated Hospital with Nanjing Medical University

Nanjing, Jiangsu, 210009, China

Location contact

Qiang Ding, Professor

CONTACT

[email protected]

+8613951731373

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

  • Female patients, aged 18-75 years old; The pregnancy test (-) and reliable contraceptive methods are required for premenopausal and perimenopausal patients;
  • Patients with the diagnosed breast cancer confirmed by core needle biopsy and unilateral operation was performed; Breast cancer patients with tumor node metastasis stage 0-III according to the 8th edition of the American Joint Commission on Cancer; Preoperative clinical examination or imaging evaluation shows that the distance between the tumor and the Nipple Areolar Complex (NAC) is more than 1cm. The tumor has a diameter of 2-3 cm and can be located in any quadrant or reduced to 3 cm through preoperative neoadjuvant chemotherapy. The distance between the lesion and the skin should be at least 8-10 mm;
  • There is no clinical or imaging evidence to prove that the tumor has invaded the skin, chest wall, or nipple areola complex;
  • There are indications for breast preservation, but the patient has a strong desire for reconstruction and is unwilling to undergo breast preservation surgery;
  • Preventive mastectomy (BRCA1/2 malignant mutation with obvious family history of breast cancer and other high-risk groups);
  • Preoperative clinical manifestations and imaging data showed no distant metastasis;
  • No history of breast cancer or other serious underlying diseases in the past;
  • Karnofsky performance status score ≥ 70;
  • Eastern Cooperative Oncology Group score ≤ 2 ;
  • The surgical procedure includes a single-port robot (intraperitoneal endoscopic surgical system) for total mastectomy with preservation of the nipple and areola, sentinel lymph node biopsy, axillary lymph node dissection, and stage I breast prosthesis implantation;
  • Participants are able to understand the research process, voluntarily join the study, sign informed consent forms, have good compliance, and cooperate with follow-up;
  • No swallowing difficulties; No shoulder joint movement disorders;
  • Complete clinical data.

Exclusion criteria

  • Male breast cancer or inflammatory breast cancer;
  • Metastatic breast cancer (stage IV); Tumor invasion of the skin, pectoralis major muscle, or NAC;
  • The clinical data is basically incomplete;
  • Previously received chemotherapy in an external hospital or has undergone tumor resection in an external hospital;
  • Bilateral breast cancer surgery;
  • Other surgical methods;
  • Preoperative distant metastasis or supraclavicular lymph node dissection;
  • Complicated with other malignant tumors or had malignant tumors other than breast cancer in recent 5 years;
  • The serious disease of non malignant tumors combined will affect the patient's compliance or put the patient in a dangerous state;
  • Dementia, intellectual disability, or any mental illness that hinders understanding of informed consent forms.

Treatment and study plan

single-port robotic-assisted nipple-sparing mastectomy and sentinel lymph node biopsy

Procedure

the single-port robotic-assisted nipple-sparing mastectomy and sentinel lymph node biopsy in the management of breast cancer

single-port robotic-assisted nipple-sparing mastectomy and axillary lymph node dissection

Procedure

the single-port robotic-assisted nipple-sparing mastectomy and axillary lymph node dissection in the management of breast cancer

Primary outcomes

  1. Local recurrence free survival rate

    Time frame: Ten years

    Local recurrence refers to the recurrence of the chest wall or breast on the same side as the surgical site.

Study contacts

Contact information is provided by the study sponsor or research team.

Qiang Ding, Professor

CONTACT

[email protected]

+8613951731373

Sponsors and collaborators

Lead sponsor

The First Affiliated Hospital with Nanjing Medical University

Other

Registry information

Official study title

A Prospective, Single-center, Single-arm Clinical Study to Evaluate the Effectiveness and Safety of the Single-port Robotic-assisted Breast Surgery in Breast Cancer

Important dates

Study start
2024
Primary completion
2026
Study completion
2028
First posted
Aug 20, 2024
Registry last updated
Aug 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.